secwatch.observer — SEC 8-K summary
======================================

Issuer:     NETWORK-1 TECHNOLOGIES, INC. (NTIP)
CIK:        0001065078
Form:       8-K
Filed at:   2023-09-06T23:59:59+00:00
Accession:  0001072613-23-000453
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Network-1's investee ILiAD reports positive Phase 2b results for pertussis vaccine BPZE1
--------------------------------------------------------------------------------

- ILiAD's BPZE1 intranasal vaccine met primary endpoint protecting against B. pertussis colonization (p=0.03) in CHAMPION-1 study.
- Vaccine reduced B. pertussis bacterial burden by 98.0% compared with placebo; no serious adverse events.
- Network-1 holds ~6.8% stake in ILiAD from $7M investment.
- ILiAD plans to present full data at World Vaccine Congress on Oct 19, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1065078/000107261323000453/0001072613-23-000453-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1065078/000107261323000453/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001072613-23-000453

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer